RYVU THERAPEUTICS S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 49.3 PLN | -1.00% |
|
-6.81% | -14.26% |
Presenter SpeechPawel Duszek (Attendees)Ladies and gentlemen, thank you very much for joining ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Ryvu Therapeutics SA, formerly known as Selvita SA, is a Poland-based company engaged in the healthcare industry. The Company is active in the pharmaceutical and biotechnology fields. It operates through two business segments. The Innovative segment develops new drugs mainly for oncology and central nervous system diseases. The Services segment is engaged in the research and development activities, such as introducing substances on the market, client service and reducing the risk. The Companyâs portfolio encompasses projects, including kinesis inhibitors platform, the platform of the metabolism for the cancer and epigenetic, among others. Ryvu Therapeutics SA is active in the domestic market and internationally, such as in the United States. It operates through unit Ardigen SA and SORS Holdings Ltd.
Calendar
2024-05-14
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
49.3
PLN
Average target price
73.12
PLN
Spread / Average Target
+48.33%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -14.26% | 286M | |
| -2.31% | 103B | |
| +0.56% | 95.71B | |
| +1.69% | 22.02B | |
| -17.37% | 20.9B | |
| -9.30% | 17.85B | |
| -41.01% | 16.21B | |
| -14.85% | 15.52B | |
| +3.21% | 13.86B | |
| +33.54% | 12.04B |
- Stock Market
- Equities
- RVU Stock
- News Ryvu Therapeutics S.A.
- Transcript : Ryvu Therapeutics S.A., 2021 Earnings Call, Mar 15, 2022
